Benorilate

Producers shown on SFDA

(Record date:30/09/2021）

Producers shown on EP

Not showing any

Staff size:100-199 persons

Registered capital:RMB 59.43 million

Producer:Wuyi Cihang Pharmaceutical Co., Ltd., formerly known as Wuyi synthetic pharmaceutical factory, was founded in 1993, covering a total area of 30000 square meters and a construction area of 11000 square meters. The main production varieties are benoylate, probucol, L-amlodipine besylate, olotadine hydrochloride and tanloxin hydrochloride. The project has been added and is under registration. The national drug approval word has an annual output of 400 tons of benoylate API.

Staff size:About 50 persons

Registered capital:RMB 500 thousand

The new plant is located in the Binhai west area of Donggang Economic Development Zone, covering an area of 131 mu with a total investment of nearly 240 million yuan. As of June 2015, it has completed the new national GMP certification of small volume injection, solid oral preparation and synthetic API workshop and obtained the certificate. The company's main product dosage forms officially reached production in 2015. The new plant has formed a production capacity of 240 tons of chemical APIs, 3 billion tablets, 50 million freeze-dried powder injections and 50 million water injections.

Staff size:200-299 persons

Registered capital:RMB 7 million 142 thousand and 857

After more than 50 years of accumulation and development, the company now has 104 drug production approval numbers, including 20 APIs and 84 preparations. The leading varieties of API are acetaminophen, chlorpipetin hydrochloride, nefopam hydrochloride, procaine hydrochloride, diphenhydramine hydrochloride, famotidine, dioxpromazine hydrochloride and levofloxacin mesylate. The annual output of preparations is more than 2 billion tablets, mainly including chlorpipetin hydrochloride tablets and compound paracetamol diphenhydramine tablets. The company has import and export rights, and its products are mainly exported to India, Hong Kong, Macao, Taiwan and other countries and regions. The company has passed GMP certification and COS certification, and is applying for FDA certification to obtain a pass for products to enter the European and American markets.

Staff size:About 400 persons

Registered capital:RMB 50 million 

The enterprise covers an area of more than 36 Mu and a construction area of more than 20000 square meters. Its production scope includes chemical APIs, sterile APIs, tablets, hard capsules, powder injections, granules, dry suspensions, oral liquids and oral solutions. It has independently developed, developed and produced 154 approvals, including 142 preparations and 12 APIs; The Department and all its production lines (nine dosage forms and seven workshops in total) have passed the new version of GMP certification.

Staff size:400-499 persons

Registered capital:RMB 83.98 million

Producer:Shandong Fangming Pharmaceutical Group Co., Ltd. is a comprehensive pharmaceutical production enterprise integrating science, industry and trade. It is a secondary unit of Hongye group, one of China's top 500 enterprises. At present, the company mainly produces 5 dosage forms such as small volume injections, tablets, hard capsules, ointments and APIs. There are 128 national drug approval drug document numbers, covering 12 treatment fields, of which 25 varieties are shortlisted in the national catalogue of essential drugs. There are four factories and six subsidiaries, mainly including western medicine preparation, biopharmaceutical and fine chemical industry. The total area is more than 2000 mu.

Staff size:700-799 persons

Registered capital:RMB 210 million

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978